Skip to main content

Dyskinesias

8
Pipeline Programs
6
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
6
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Abbott
AbbottABBOTT PARK, IL
1 program
1
Levodopa-carbidopa intestinal gelPhase 31 trial
Active Trials
NCT00360568Completed62Est. Oct 2012
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
Levodopa-carbidopa intestinal gelPhase 3
Sandoz
SandozAustria - Kundl
4 programs
4
AFQ056Phase 21 trial
AFQ056Phase 21 trial
AFQ056Phase 21 trial
AQW051Phase 21 trial
Active Trials
NCT01491932Completed129Est. Oct 2013
NCT01491529Completed154Est. Apr 2013
NCT01385592Completed78Est. Sep 2012
+1 more trials
Contera Pharma
Contera PharmaDenmark - Hørsholm
2 programs
2
JM-010Phase 21 trial
JM-010 group APhase 21 trial
Active Trials
NCT05516875Terminated6Est. Jun 2024
NCT03956979Completed89Est. Mar 2024
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
LevodopaN/A1 trial
Active Trials
NCT00467597Completed36Est. Oct 2013
Novartis
NovartisBASEL, Switzerland
1 program
AFQ056PHASE_2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AbbottLevodopa-carbidopa intestinal gel
Contera PharmaJM-010
Contera PharmaJM-010 group A
SandozAFQ056
SandozAFQ056
SandozAFQ056
SandozAQW051
Oregon TherapeuticsLevodopa

Clinical Trials (8)

Total enrollment: 625 patients across 8 trials

NCT00360568AbbottLevodopa-carbidopa intestinal gel

Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects

Start: Jun 2009Est. completion: Oct 201262 patients
Phase 3Completed
NCT05516875Contera PharmaJM-010

Open-Label Extension Study of ASTORIA

Start: Jan 2024Est. completion: Jun 20246 patients
Phase 2Terminated
NCT03956979Contera PharmaJM-010 group A

A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia

Start: Jul 2019Est. completion: Mar 202489 patients
Phase 2Completed
NCT01491529SandozAFQ056

Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Start: Apr 2012Est. completion: Apr 2013154 patients
Phase 2Completed
NCT01491932SandozAFQ056

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Start: Mar 2012Est. completion: Oct 2013129 patients
Phase 2Completed
NCT01385592SandozAFQ056

Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Start: Nov 2011Est. completion: Sep 201278 patients
Phase 2Completed
NCT01474421SandozAQW051

Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

Start: Sep 2011Est. completion: Feb 201371 patients
Phase 2Completed
NCT00467597Oregon TherapeuticsLevodopa

Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1)

Start: Apr 2006Est. completion: Oct 201336 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.